During the past decade numerous advances have been made in understanding the structure, mechanism and clinical properties of dihydropteridine reductase. An attempt is made here to delineate the current status of this essential enzyme by describing its structural features, its kinetic mechanism, the cloning and expression of both rat and human enzyme forms, the solution of their crystal structures, their classification as members of a large family of short chain dehydrogenases, and finally a brief description is included indicating how current molecular biological applications have allowed the clinical definition of the aberrant form of phenylketonuria caused by a defective reductase.
Introduction and history
Naturally occurring pteridines, which usually contain 2-amino and 4-hydroxyl substituents can be separated into two distinct classes. One class contains the pterins of the folic acid series which possess a p-aminobenzoylglutamate (or polyglutamate) moiety substituted into the heterocyclic nucleus via a 6-methylene group, and the second class contains molecules possessing other substituents at the 6-position, e.g., biopterin, neopterin and xanthopterin. Since the discovery and classification of pteridines in the early part of this century (1 , 2) a large number of pteridine-or folate-requiring enzymes have been identified and their mechanisms of action examined (3) . Many investigators have been intrigued by the diverse functions of pteridines when they act as cofactors or substrates in enzymatic reactions, by their unusual organo-chemical properties. by their preference for hydroxylic solvents and by the presence in their heterocyclic nucleus of many centers for protonation, which often influence binding and reactivity. Important metabolic functions of conjugated pteridine-mediated biological reactions include the one-carbon insertion reactions fundamental to purine biosynthesis (4. 5), the vitamin B,Tmediated synthesis of methionine (6) , and the synthesis of thymidylate (7) . The most important unconjugated pteridine-containing enzymatic systems are associated with the metabolism of the aromatic amino acids (8) (9) (10) .
Dihydropteridine reductase and phenylalanine. tyrosine and tryptophan hydroxylases play vital roles in the synthesis of the catecholamines dopamine. epinephrine and serotonin and indirectly can also intluence the generation of the melanin pigments. Tetrahydrobiopterin is an essential cofactor in these metabolic pathways and facilitates the monooxygenase activity which ultimately leads to the hydroxylation of the aromatic amino acid substrate (Figure Figure I. The participation of DHPR in the conversion of quinonoid dihydrobiopterin (R=dihydroxypropyl) to tetrahydrobiopterin, which is used as a cofactor in the aromatic amino acid hydroxylations.
1). In these reactions phenylalanine, tyrosine and tryptophan are converted to tyrosine, dihydroxyphenylalanine and 5-hydroxytryptophan, and the cofactor undergoes oxidation to a quinonoid dihydro form of biopterin (q-BH2). q-BH 2 then becomes the substrate for DHPR and in an NADH-mediated reaction is recycled to BH4. The principal metabolic end products of these BH4-dependent amino acid hydroxylations have important cellular functions. Dopamine (3,4-dihydroxyphenyIethylamine) is a central nervous system neurotransmitter representing more than 50% of the total catecholamine content in the brain and spinal cord of many species (II). and norepinephrine (3,4-dihydroxyphenylethanolamine) is the chemical transmitter in sympathetic neurons and is an essential neurotransmitter in brain tissue. Epinephrine (N-methyl-l(3-4-dihydroxyphenyl)ethanolamine) is best known as an important hormone of the peripheral atKonomic system, although it also functions as a transmitter in the olfactory system and as a central nervous system neurotransmitter (12) . Serotonin (5-hydroxytryptamine) is an important brain neurotransmitter that exerts widespread influence over arousal, sensory perception, emotion and higher cognitive functions (13) . The defective function of the hydroxylation process has long been recognized clinically in the autosomal recessive disease hyperphenylalaninemia or phenylketonuria (PKU) (14) . Originally this disease was considered to correlate only with a defective phenylalanine hydroxylase, but a significant number of cases have now been identified whose cause lies in a defective DHPR function or aberrant biosynthesis of the tetrahydrobiopteri n cofactor (15, 16) . The enhanced complexity resulting from an additional requirement for the cofactor in catecholamine biosynthesis makes the standard phenylalanine-free diet protocol ineffective treatment for this group of patients and emphasizes the importance of characterising these alternate defects. Currently, diagnosis is usually achieved by further serological analyses (17) , but clearly a more precise understan·ding of DHPR action could be of value in interpreting clinical situations relating to a malfunctioning reductase. For example, if the genetic defect in DHPR deficient patients can be identified, as has in fact been recently reported for several patients (18, 19) , the lesion can be related to the structure, and the cause for diminished enzymatic activity may be identified at the molecular level. In addition, as the data base of defective structures increases, a possible pattern of common causal features may evolve via correlation with the X-ray crystallographic s~ructure and targets may he created for molecular corrective action.
The purpose of this review article is to outline current knowledge relating to DHPR with a particular emphasis on more recent developments in the structural and mechanistic understanding of this enzyme. Excellent reviews by Annarego et al. (20) and Shiman (8) have covered many of the salient features of this enzyme and therefore areas covered in depth by these earlier reviews will receive only limited coverage in the current report.
Source, purification and properties of DHPR DHPR has been obtained from several mammalian sources that include sheep brain and beef adrenal medulla (21) , the liver of sheep (22) , beef (23) . rat (24, 25) , monkey and human (26, 27) , and also from various murine (28) and human cell samples (29, 30) . In addition, the enzyme has been isolated from species of Pseudomonas (31), E~cherichia coli (32) , and Crithidia fasciculata (33). From mammalian sources the tissue is usually diced and homogenised in the presence of buffer or dilute acetic acid containing a cocktail of protease inhibitors and solid material is separated by centrifugation. The active component is then concentrated by ammonium sulfate fractionation and after dialysis is subjected to a variety of chromatographic separation procedures. The earlier methods relied heavily on DEAE-cellulose or-sephadex fractionation but more recent efforts have employed specific affinity matrices or dye containing matrices such as Procion Red or Cibacron Blue. In some instances a further hydrophobic chromatographic step followed by Sephadex or Sephacryl sizing columns has allowed isolation of a completely homogeneous product (34) . A typical protocol is shown in Table 1 . It is interesting to note the progression of enhanced specific activities (from 2.5--:>400 units/ mg protein) over the years with th e improvement in purification procedures. It is evident that the blue dye column materials, known to recognise dinucleotide protein binding sites, are particularly effective in ensuring a product of higher specific activity is obtained (35) . This observation correlates well with the structural and kinetic properties of the enzymes, outlined elsewhere in this report, that illustrate the enhance stability of the protein when bound to its dinucleotide cofactors. The isolation of the bacterial and flagellate reductases essentially requires the large scale growth of cultures, separation and cell lysing followed by centrifugation and ammonium sulfate fractionation of the supernatant. The dialysed active fractions are then purified by various ion-exchange and sizing matrices. Since E. coli has also become an optimal vehicle for expressing the wild type and mutant mammalian enzymes, a procedure has been adopted very similar to that described for the wild type mammalian enzyme (34) for purifYing these products to homogeneity (36, 37) ( Table 1) . Of the non-mammalian enzymes, that derived from E. coli is best characterised and has bee n shown to contain bound FAD (32) . It exhibits similar properties to those of th e reductases isolated from Pseudomonas and C. fasciculata. However, as a class they are sufficiently different to those of the mammalian enzymes, particularly in chromatographic behavior, that they will be excluded from this review. In addition the NADPH-requiring pteridine reductases, also occurring in mammalian liver (38) have sufficiently differing properties to allow their exclusion.
Common features of the mammalian NADH-requi ring reductases include a molecular weight of approximately 51,000 composed from two identical subunits. Earlier isoelectric focusing studies had suggested some disparity in subunit composition (39) , but more recent cloning and expression of the enzyme cDNA would favor identity of the two subunits (40 .2m (ku-O.02 f,lM) over NADPH (kct-2.2 f,lM), although the possibility does exist that in vivo the relative concentrations of reduced pyridine dinucleotides might allow NADPH to function as the reductant in this situation. The substrate is invariably a 'quinonoiddihydropteridine and not the more stable 7,8-dihydroisomer favored by dihydrofolate reductase (DHFR) (Figure 2 ). The specific activities of highly purified sa mples range from 300 to 400 units/mg protein for both rat and human samples. The affinity for the oxidised dinucleotide is very low (k,-O.l mM) and a single broad pH optimum in the vicinity of pH 7 is observed. The enzyme is somewhat hydrophobic a nd is therefore susceptible to purification by phenyl sepharose chromatography. The apo enzyme can be titrated with p-chloromercuribenzoate, 5,5' -dithiobis (2-nitrobenzoic acid) and N-bromosuccinimide with complete loss of activity in each case, however. bound NADH will offer protection against inactivation but neither quinonoid dihydro substrate nor tetra hydro product provide any protection (41) .
Assay
Several assays have been developed for the estimation of DHPR (22, 23, 42) . All can be criticised because of the instability of the enzyme substrate and the difficulty of generating the substrate in th e assay. The general aim of the assay is to create a high concentration of the quinonoid dihydropteridine substrate, usually from the tetrahydro form , and observe its re-reduction by NADH. The change in absorbance at 340 nm can then be related to enzy-matic activlty. Unfortunately the quinonoid pterin substrates have varied stabilities with products fonning that have differing spectral properties. In addition non-enzymic oxidation of NADH occurs· at an appreciable rate and can also be a source of error. The favored methods for generating the quinonoid form are to use peroxide and peroxidase, ferricyanide, dichlorophenol indophenol and in earlier papers the associated amino acid hydroxylating systems for which the tetrahydropterin is a substrate. An alternate spectral procedure is to observe the reduction of ferri-cytochrome c at 550 nm by the tetrahydropterin fonned in the reaction. This assay depends on initial incubation to generate the pterin dihydro quinonoid fonn to create a concentration plateau prior to enzyme addition, but suffers from similar problems to those occurring in the other assay procedures. A" there is clearly no completely satisfactory approach it is probably advantageous to choose a procedure, buffer, temperature and pH convenient to a particular laboratory and ensure that all assays are then self consistent. In this way comparative assays performed under these conditions can be readily interpreted.
Substrates
The natural substrate for the enzyme in mammalian tissue has been identified as quinonoid dihydrobiopterin (43) (Figure 1 ). The substrate is generated from (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin by various oxidising agents in vitro or during the course of the aromatic amino acid hydroxylations in vivo. Until recently specific chiral reduced biopterin substrates were not readily available but fortunately DHPR is tolerant of alternate substituents at the 6-and 7-positions and therefore the methyl analogues have been used extensively. Substrates containing a proton as the second substituent at C6 are relatively unstable and are therefore generated in situ when required. Their mode of change is either via isomerisation to the more stable 7,S-dihydro isomer, or by substituent loss (44) . The 7,S-dihydro isomer is not a substrate for DHPR. More stable quinonoid dihydro structures have been created in which the C6 proton is replaced by either a deuterium or second alkyl or aryl substituent (45, 46) . Unfortunately the enzyme is not so tolerant of the disubstitution, as the KM values increase markedly for such derivatives. The 4-hydroxy or keto substituent is also important for activity as the 4-amino analogs are not substrates (47) , however. again some license is offer-: d to 2-amino substituent replacements (4S). The second substrate for DHPR is NADH. Evidence is derived from a twenty-fold magnitude distinction in KM value between it and NADPH for the enzyme (42, 49), a marked difference in 1<. . . 1 values from fluorescence titration experiments and the observation, in the crystallographic structure of the rat binary complex, of tight hydrogen bonding between Asp 37 and the adenine ribose 2',3' -hydroxyl substituents (50) . The enzyme also shows strong affinity for the inactive thio-NADH (kd-0.OO5 11M) and adenine-uracil (kd-0.35 11M). The tight binding of NADH to DHPR appears essential for retaining protein stability and for creating the enzymatic site as will be described further in the kinetic and crystallographic sections of this review.
Kinetics
Limitations in the assay procedures discussed earlier have restricted the precision with which the mechanism can be analysed kinetically, however several studies favor an ordered mechanism in which NADH binds first to thc enzyme followed by the quinonoid dihydropteridine substrate. The tetrahydropteridine product then leaves followed by NAD j (51) (52) (53) . It is suggested a change in enzyme conformation at some stage in the sequence provides a rate limiting step. Several lines of evidence support the initial nucleotide binding. For example, the enzyme can bind pyridine nucleotides in the absence of pterins, whereas the reverse is not true. and the enzyme can be purified by NAD + -agarose, AMP-agarose or Cibacron blue agarose also in the absence of pterin substrate or product. Probably the most compelling evidence stems from the recent crystallographic work that demonstrates the pterin binding site is partially created by the presence of the bound dinucleotide cofactor (54) .
Most reports with enzymes from various mammalian sources show NADH to be the favored cofactor quinonoid dihydrobiopterin up to-40 11M for the unresolved isomers of the 6-methyl or 6}-dimethyl quinonoid dihydropteridines, commonly used as substrate analogs in routine assays because of their being more readily accessible. It is interesting to note that 1<... .", is consistently higher with the methyl (55) , that the kJ value for NADH suggests an on rate commensurate with the diffusion controlled limit for this substrate (52) , and that the transfer of hydrogen from NADH in the reaction is exclusively from the l3-face (i.e., the pro-S hydrogen atom) (56) .
The recently reported characterisation of DHPR cDNAs and their expression in Escherichia coli has allowed accurate sequencing of the enzyme and mutagenesis experiments to be carried out (57) (58) (59) . It is apparent that the enzyme contains a characteristic l3al3 Rossman fold (60) in the nucleotide binding region and that in the clone obtained from a rat liver source, aspartate-37 is crucial to the binding of the adenine ribose, via close hydrogen bonding (50) . It is this interaction that creates the preference the enzyme exhibits for NADH. An isoleucine mutant has been formed and as expected the differential affinity of the enzyme for NADH rather than NADPH has been diminished. In fact kcaJ KM for the NADH catalysed reaction falls from 12 f..lM-IS-1 to 1.2 11M-l s-1 with the mutant, whereas that for NADPH rises from 0.25 --> 0.6 IlM-IS-I , which is now close to half the figure for NADH, demonstrating a similar stickiness for either dinucleotide. Selected examples of kinetic constants are illustrated in Table 2 .
Inhibition
Considerable effort has heen expended towards determining inhibitors with specificity for DHPR. Unfortunately, despite the superficial similarity to DHFR no compound has been discovered with the affinity amethopterin (methotrexate) displays for this latter enzyme. In fact, aminopterin (21 , 47) , iodoaminopterin, and amethopterin (61) , are all inhibitors of DHPR (Ki-25 11M), however, the kinetic analyses are inconsistent regarding competitive, noncompetitive or uncompetitive interactions with pterin substrate. It is of interest to note in this context that whenever the DHPR-NADH binary crystal is soaked in solutions containing one of the above inhibitors prior to crystallography, the structural pattern emerging indicates a loss of the dinucleotide, suggesting the inhibitor may somehow disrupt the dinucleotide binding site. The crystallographic ternary complex suggests that both extremities of the quinonoid pterin nucleus may be solvent accessible (54) , therefore inhibitor design may restrict substitution to the immediate vicinity of the pterin ring and mechanistically may require a quinonoid bond distribution. The most interesting compounds falling into this category (Figure 3 ) have been reported by Armarego and associates (62) . In these structures, the crucial 6-position of the pterin is replaced by a substituted nitrogen atom, thus locking the structure into the quinonoid form. These compounds do in fact appear to be good inhibitors with Ki-IO --> 100 IlM.
At one time it was considered that products of the catecholamine biosynthetic pathways might offer feedback inhibitory control of DHPR and thus afford regulation of the enzyme in vivo (63) . It was an interesting idea but it would appear the compounds would rapidly degrade to quinone structures that interfered with accurate estimates of NADH concentrations in assays and thus gave erroneous figures, suggesting inhibition (64).
Antibodies
Antibodies, both polyclonal and monoclonal, have been raised against DHPR samples from various sources (65) (66) (67) and against pterins bound to albumin (68) . The resultant immunoglobulins have been used for various purposes. Polyclonal antibodies raised by standard techniques have been u sed to demonstrate the lack of DHPR in patients suffering from an aberrant PKU in which the reductase is missing, as a means of quantitating DHPR by enzyme immunoassay techniques (69) , and for estimating the enzyme in human blood cells. A novel approach pursued by Cotton and his associates (70) has led to the generation of anti-idiotypic monoclonal antibodies, which have then been used quite effectively to probe differing folate and pterin binding enzymes' to help delineate pterin binding sites on the protein surfaces. This approach has proven useful, however, conclusions should be reviewed with some caution as the contours of the anti-idiotypic antibody determinant may not be sufficiently distinctive to categorically distinguish the pterin binding site from sites for other similar molecules such as pyrimidines or nucleotides. Thus deductions drawn regarding the similarity of DHFR and DHPR (68) could perhaps be considered a little premature, since when the structures were subsequently compared crystallographically (54) , there appeared to be rather limited similarity between the two enzymes.
Cloning, expression, mutagenesis and PCR Progress in structurally characterising DHPR made significant advances with the application of Pteridines / Vol.4 ! NO. 4 John M. Whiteley er aJ.: Dihydropteridine reductase current molecular biological procedures to the elucidation of its sequence from both rat and human sources (57, 59) . In both cases oligonucleotide probes were used to identify the enzyme cDNA in phage libraries derived from rat and human sources respectively. Expression in both E. coli and COS cells has led to both sequence identity (Figure 4 ) and the ability to express the respective proteins in good yields, particularly from the E. coli source. Moreover, the application of mutagenesis techniques has further allowed specific amino acid replacements to be made such that the functionality of these specific units can be identified with regard to their binding of substrate, cofactor and their influence on reaction rate and mechanism (36, 50) . Table 3 illustrates mutant enzyme sequences that have been created with the rat enzyme and the effect on kcat is shown. It is interesting to note (Figure 4 ) that the transition from rat to human enzyme requires merely the insertion of three extra alanines and deletion of one serine at the N-terminal plus an additional ten conservative random replacements in a protein of approximately 240 amino acids.
As was indicated earlier, naturally occurring mutational changes in the sequence of human DHPR can lead to aberrant forms of PKU. Many of these errors have been identified (Table 4) particularly by Cotton and his associates (71) . The usual procedure is to obtain a fibroblast culture or white cell pellet. then generate a cDNA library that allows amplification of the DHPR component by PCR techniques Figure 4 . The superposItion of the equivalent Ca-carbon .;lums of human and rat DHPR. In particular the a-carbons ,I' residucs 8-243 from the human enzy me are superimposcd "ith the a-carbons of residues 5-240 of the rat liver enzyme. The trace of the human structure is shown by the heavier II ne. Specific amino acid numbers are shown to illustrate the rat-human amino acid replacements using the human numbering system (see Fig. 4 ).
and subsequent sequencing identifies the errors. Figure 5 illustrates the human DHPR structure obtained from X-ray crystallography. The occurrence of the currently known errors can be determined from the a-carbon backbone of this structure. As might he expected a priori the errors appear to interfere \\ith substrate or cofactor binding, dimer formation or the active site (see next section).
X-ray crystallography
The purified rat liver DHPR has been crystallized from a polyethylene glycol-ethanol mixture using a vapor diffusion method (34, 54) . It crystallized in two different crystal forms. The first crystal fonn amenable to X-ray diffraction studies was monoclinic, space group C2 with a=224.3 A, b=46.5 A, c=94.9 A, 13=99.0° and contained two dimeric molecules in the asymmetric unit ( Figure 6) ; however, attempts to find good isomorphous heavy atom derivatives were unsuccessful. Fortunately, an orthorhombic fornl, C222 1 ' Figure 6 , and this is mediated by a four helix bundle motif (two helices from each protomer having an unusual right-handed twist). Surprisingly, DHPR is structurally and mechanistically distinct from DHFR appearing to more closely resemble certain nicotinamide dinucleotide requiring flavin-dependent enzymes such as glutathione reductase.
Attempts to generate a crystalline ternary complex have so far been unsuccessful. For example. it is known that methotrexate. aminopterin and iodoaminopterin are inhibitors of DHPR however, attempts to diffuse these compounds into the binary structure have been fruitless. In fact, as was stated previously, evidence from this and kinetic work suggest these inhibitors may actually compete for the dinucleotide rather than pterin binding site. The orthorhombic C222 1 crystal form is tightly packed with a low solvent content compared to other proteins of similar size. This could be an additional reason for the difficulties experienced forming the ternary complex. The C2 monoclinic crystal form has also now been characteri<;ed to an R factor of 19.7% by a molecular replacement method using the program MERLOT. Fortunately, this crystal is more loosely packed with two dimers per asymmetric unit and offers large solvent entry ports to thc protein. It is possible this structure may be more amenable to formation of , the ternary complex.
Using molecular graphics the quinonoid dihydrobiopterin substrate has been docked at the suspected active site and using energy minimisation procedures a tentative interpretive working model for the reductive reaction that conforms to known mechanistic restrictions has been created ( Figure 7) . It is apparent that DHPR bears little resemblance to DHFR in its nucleotide binding region. A schematic comparison is shown in Figure 8 . In the latter case the nicotinamide component of the dinucleotide resides close to the N-terminus of the enzyme, whereas in the case of DHPR the reverse is true and the nicotinamide component is towards the center of the molecule and creates one face of the active site. Such a configuration is consistent with enzymes in which hydride transfer from a reduced dinucleotide to a flavin can occur in reactions such as the NAD PH -mediated glutathione reductase and p-hydro- John ~1. \\hit.:k~ de l i. Dihydropteridine reductase xybenzoate hydroxylase. Such analogies are particularly attractive, as the quinonoid dihydropteridine substrate contains the crucial conjugated chromophore of the flavins and thus one might expect DHPR to have many mechanistic and structural similarities to flavin-mediated hydroxylation reactions. Comparable reactivities have been suggested previously, but only with the enhanced clarity of the emerging more definitive DHPR structure ' can hypotheses now engender a se I11 blance of proven credibility.
The human DHPR has also been crystallized and the structure was solved using 2.5 A data and has been refined to an R value of 16.9%. It also crystallised in both the monoclinic and orthorhombic space groups and the latter was more favorable to rapid solution. The superposition of the structural backbone of human and rat DHPRs are shown in Figure 5 . It is interesting to note that despite the sequential amino acid changes there are only small differences in the two structures, in fact the r.m.s.
deviation for all the Ca atoms is only 0.27 A. The ten replacements occurring in the transition from rat to human DHPR are also shown in this figure.
The average temperature factor changes associated with the amino acid changes occurring in the transition from rat to human DHPR are delineated in Table 5 effect on enzyme stability. On the other hand, when huried residues with low temperature factors are mutated, they reduce the stability of the protein. For example with T4 lysozyme such a mutation typically caused the loss of stability by 4 kcal/mole. The average temperature factors for all the residues in human and rat DHPR enzymes are 10.6 . .\2 and 14.2 ,.\2 respectively. Of particular note is that two of the random insertions Val 39 (lie 36 in the rat) and lie 51 (Val 48 in the rat) have low temperature factors suggesting the replacement could lead to significant energy changes. However, the two changed residues occur on adjacent J3-strands (B and C) and the nature of the change and position ensures that this is both small and compensatory. In contrast, all of the other eight random substitutions are highly exposed to solvent and are accompanied by large thermal parameters. For example, two aspartate residues (73 and 230) in the rat are replaced by glutamate residues (76 and 233) in the human enzyme and the asparagine and lysine residues (215 and 216) in the rat become lysine and asparagine residues (218 and 219) in the human situation. Probably the most drastic change is that of serine 169 to proline 172 in the human protein.
The introduction of the proline residue imposes a restriction on the <I> rotation at this residue. However, the (<I>, \jI) values of Ser 169 are -58° and l3r respectively and these values fall in the allowed region for a proline residue (73) . Substitutions at the N-terminal region also cause little stability change in the two structures as this region of the molecule can not be clearly resolved, presumable because of a lack of structural constraints and free interaction with the solvent. It is interesting to note that the average temperature factor for the eight residues with limited constraints is 27 ;\2; almost twice the value of the average temperature factor for the rat DHPR molecule. In the human enzyme this awrage is 22.9 ;\2 which is more than twice the value of the average for all residues.
Mechanism and classification of DHPR Dihydropteridine reductase converts quinonoid dihydrobiopterin to tetrahydrobiopterin in an NADHmediated reaction. Dihydrofolate reductase generates tetrahydrofolate (FH4) from 7,8-dihydrofolate (FH 2 ) in an NADPH-mediated reaction. Both products have the 5,6,7,8 tetrahydropteridine structure but have differing substituents at the 6-position; BH4 having a dihydroxypropyl group, whereas FH4 has a para-aminobenzoylglutamate component ( Figure 9 ).
There is clearly a superficial similarity insofar as each enzyme employs a reduced dinucleotide cofactor to convert a dihydropteridine to its tetrahydro counterpart. However, upon further examination this initial observation proves to be deceptive. For example, DHPR is a dimer of M r -5l,000 daltons (58), whereas DHFR usually exists as a monomer with M r -18 --> 22,000 daltons (74) and DHPR has a clearly enhanced specificity for NADH (56) which contrasts with the preference for NADPH exhibited by DHFR (74) . The specificity for the dihydropteridine substrate also differs. Although a quinonoid dihydrofolate can be generated that can be a substrate for DHPR the quinonoid form canot be a substrate for DHFR nor can the 7,8-dihydro form be a substrate for DHPR. This is realy not surprising as the ground state distribution of electron density around the two dihydropteridine rings is distinctly different (1. Gready, personal communication) and would suggest a priori an altered receptor site might be necessary for reactivity. Moreover, the specific activities of the two enzymes are very different (approx. 300 and 25 units/ mg protein for DHPR (56) and DHFR (75) respectively), suggesting both a different mechanism and site of reaction for the two enzymes. This is further substantiated by the clear Figure 9 . The biosynthetic reductive pathways converting qBH, and 7,8-FH, to BH4 and FH4 respectively. lack of affinity exhibited by DHPR for the oxidised dinucleotide product of reaction, NAD + (76) which is a very different situation to that of DHFR, where NADP + has been identified as a participant in the kinetic turnover of the enzyme (77) and has also been used in the generation of ternary complexes that have sufficient stability to be examined by Xray crystallography (78) . Other experimentally observed differences would include a single pH optimum for DHPR (54) compared to the two for DHFR (74) the hydrophobic nature of DHPR, exhibited by its binding to phenyl sepharose (34) and the lack of unique titrCltable amino acids which can cause abrupt changes in specific activity (41) . This contrasts markedly with the characteristic enhancement of eukaryotic DHFR specific activity when this enzyme is titrated with mercury salts (74) . Moreover, there is no sequence correlation between the two enzymes (58, 74) .
The crystal structures of DHPR and DHFR show that each enzyme contains eight l3-sheets with seven parallel and one antiparallel, however DHPR has a higher a-helical content with helices E and F forming an interface for the dimeric structure. As described earlier ( Figure 8 ) the dinucleotide binding of the two enzymes is significantly different. Moreover, in DHPR the active site for pteridine binding does not exist until NADH is bound. The site is then created from the connecting regions between I3D and 131' and the crossover that occurs between I3E and I3G. Thus rather than having a separate binding domain for substrate such as is obscIyed with lactate dehydrogenase, DHPR uses a strategy of simply elaborating connecting loops to facilitate substrate binding that is intimately connected to a requirement for prior NADH interaction. In fact the quinonoid structure of the substrate pteridine has distinct similarities to that of the l1avin molecule and thus mechanisms of reduction such as those described for the NADPH-mediated glutathione reductase (79) and p-hydroxybenzoate hydroxylase (80) appear to be better analogies for understanding the DHPR mechanism of action. In crystallographic analyses of glutathione reductase the reduced nicotinamide ring is aligned parallel to the l1avin such that a hydride transfer is facilitated to N5 of the l1avin. A similar situation can be created using graphic techniques with DHPR ( Figure 7) .
In this figure, the reduced nicotinamide is oriented such that transfer of the C4 hydride can readily occur to the N5 position of the pteridine. Such a transfer has been suggested previously on structural grounds (57) , by the low ground state electron density at N5 (J. Gready, personal communication), and by analogy with flavin mediated reductive processes (79) . In this instance. however. the transfer of hydride must again be followed or preceded by a proton transfer to achieve a fully reduced pteridine. Several possibilities exist for the site of protonation (R I) (Figure 10) .
Experiments conducted with tritium-labeled NADH have indicated that hydride is transferred to a solvent exchangeable position on the pteridine ring (56) and mechanistically this type of center also accommodates the proton, therefore labeling experiments cannot define the reductive centers. Reports have also indicated little energy difference between the exocyclic and endocyclic isomeric forms of the quinonoid dihydropteridines (81) therefore a priori it is difficult to assign a certain course of reductive action. Nevertheless, specific features of the DHPR active site containing a "docked" qBH2 suggest a course of reaction in which the Tyr 146 XXX Lys 150 motif palticipates in proton donation. A structure can be realised in which the hydroxyl substituent of Tyr 146 is within 3 A of the 4-oxo group on the pteridine, hence direct protonation could occur. However, more recent high resolution X-ray structures suggest a water molecule is situated such that proton donation could be translocated to N3 of the pteridine. Both the lysine £-amino groups and tyrosine hydroxyl groups have pK s -lO, thus it is possible that a protonated Lys 150 influences Tyr 146 sufficiently so that it or the adjacent water molecule is the source of the proton. Compelling supportive evidence stems from the observation that a Lys ISO GIn mutant has a specific activity of only 50 units/ mg protein compared to-300 units/ mg for the natural enzyme and that a Tyr 146 Phe mutant has virtually no activity, yet has an equally strong affinity for NADH as the wild-type enzyme, and also responds to the rat DHPR polyclonal antibody. However, Lys 150 is also close to the nicotinamide ribose hydroxyl groups therefore an additional function of this amino acid could be to aid in the correct orientation of NADH relative to substrate.
It has been reported that the Tyr XXX Lys pattern exocyclic qBH2 endocyclic qBH2 Figure 10 . Differing possible NADH-mediated reductive routes for the quinonoid dihydropteridine when bound to DHPR.
is present throughout a diverse group of enzymes classified as the short chain dehydrogenases (82) (Figure 11 ). Each has a binding domain for a dinucleotide cofactor and each has a second domain containing the sequences outlined in the figure. In every case, and more than twenty examples are now known, the Tyr XXX Lys motif appears essential for enzymatic activity. One other crystal structure for an enzyme of this class has been reported, that of 20~DH (83) and here again it is possible that the tyrosine participates, directly or indirectly via water molecules, in proton donation. A unique distinctive feature between the dehydrogenases and Dl-fPR is that the alanine group, thirteen amino acids upstream from the tyrosine, is replaced by serine. Structural analysis demonstrates it is sufficiently close to the active site to interact with the tyrosine hydroxyl. This interaction could be crucial to the ambivalent direction of reaction occurring with the dehydrogenases. Nevertheless, it is clear that the relevant energy differentials between the respective substrates and products is also instrumental in driving the reaction to completion.
Currently it would appear that DHPR has only superficial similarities to DHFR that in terms of hydride transfer it has common mechanistic features to flavin reduction pathways and yet its overall structural assembly suggests a close familial resemblance to the short chain dehydrogenases.
Clinical
During the course of the past two decades it has hecome apparent that PKU has a rather complex etiology. Earlier it had been identified as a defect 1 35 14 0 (87), it became apparent that both the biosynthetic route to the hydroxylase cofactor, tetrahydrobiopterin, and the enzyme DHPR that recycles this cofactor could be defective ( Figure 12 ). Alternate therapies based on these conclusions were therefore developed (88) , and additional methods for clinical analyses and defect detection were discovered (89) . In several cases a lack of, or deficiency in DHPR was confirmed. The DHPR gene has been identified with chromosome 4 (90) and RFLP procedures have been employed in prenatal screening of DHPR deficiency (91) . Using current biological techniques Cotton and various associates have additionally been able to detect the specific gene defects occurring in several patients exhibiting DHPR deficiency (71, 92) . Table 4 illustrates the effect these defects have on the complementary protein and where these changes occur in the X-ray crystallographic structure can be traced in Figure  5 . It is interesting to note that the changes interfere with dimer formation, dinucleotide binding and the active site. Clearly the possibilities afforded by the developing areas of gene therapy (93) could perhaps very soon be applied to correct this debilitating metabolic defect.
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'q' BH, Figure 11 . Alignment of a selected region of fi ve short chain dehydrogenases including DHPR. Strictly conserved resi· dues are outlined. Residue numbers at the start of each line refer to each sequence and those above to the rat liver DHPR. 
~ DHPR (2) Figure 12 . The three pathways where genetic mutations can occur causing altered protein structures that affect enzymatic action and ultimately give rise to symptoms of PKU in patients.
Conclusion
DHPR has come a long way from being the parochial "sheep liver enzyme". It has been isolated from a great many other sources and both human and rat enzymes have been cloned and expressed in E. coli. The crystal structures from each of these sources have been obtained at high resolution and it is clear that any resemblance to DHFR is superficial. Mechanistic analogies are more related to flavin reduction and there is clearly an interesting structural and mechanistic resemblance to a larger family of short chain dehydrogenases. Complete elucidation of the en0'me mechanism still awaits both the development of a natural ternary complex followed by its X-ray solution, and the resolution of the precise interplay of amino acids, identified via both sequence alignment and mutational experiments, as participating at the enzyme active site. The similarity exhibited by DHPR to the dehydrogenase family may go some way towards explaining the somewhat puzzling ubiquitous distribution of the reductase in tissues, where it appears to have no purpose, in that it may be a refinement of a common gene that originally had a more general purpose. The unique feature of the TyrXXXLys sequence is clearly an important conserved evolutionary feature for dealing with the reduction of a polarised double-bond, or the dehydrogenation of the complementary reduced species. It is possible that this new interpretation of DHPR at the molecular level might assist the clinical understanding of aberrant PKU caused by a reductase deficiency and that it might in the foreseeable future contribute to improved therapy.
